Reply

We appreciate Drs Anne and Oleti's interest in our article. First, to address the relevance and justifiability of our study, despite improved survival of preterm infants over the last several decades, there has not been a parallel decrease in the incidence of bronchopulmonary dysplasia (BPD). In addition, as stated in our paper, recent published data confirm that up to 9% of very low birth weight (VLBW) infants continue to be exposed to steroids for the treatment of evolving BPD. Despite research on postnatal steroid use, no definitive recommendations exist to guide this therapy, and  clinical applications vary widely, with a “less is more” approach often advocated.
Source: The Journal of Pediatrics - Category: Pediatrics Authors: Tags: Letter to the Editor Source Type: research